Loading clinical trials...
Loading clinical trials...
A Multicenter, Prospective, Non-randomized, Phase I-II Trial to Assess the Efficacy and Safety of the Combination of Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients
Conditions
Interventions
Quizartinib
Fludarabine
+3 more
Locations
20
Spain
Complexo Hospitalario Universitario A Coruña
A Coruña, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Institut Català D'Oncologia-Hospital Germans Trias I Pujol
Badalona, Spain
Institut Català D'Oncologia-Hospital Duran I Reynals
Bellvitge, Spain
Hospital Universitario Puerta Del Mar
Cadiz, Spain
Hospital San Pedro de Alcántara
Cáceres, Spain
Start Date
December 26, 2019
Primary Completion Date
December 1, 2023
Completion Date
December 1, 2023
Last Updated
March 14, 2022
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT05886049
Lead Sponsor
PETHEMA Foundation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions